2020
Cholinesterase and Tyrosinase Inhibitory Potential and Antioxidant Capacity of Lysimachia verticillaris L. and Isolation of the Major Compounds
OZGEN, U., S. O. SENER, Karel ŠMEJKAL, Jiří VÁCLAVÍK, D. F. SENOL et. al.Základní údaje
Originální název
Cholinesterase and Tyrosinase Inhibitory Potential and Antioxidant Capacity of Lysimachia verticillaris L. and Isolation of the Major Compounds
Autoři
OZGEN, U., S. O. SENER, Karel ŠMEJKAL (203 Česká republika, domácí), Jiří VÁCLAVÍK (203 Česká republika, domácí), D. F. SENOL, Orhan I ERDOGAN, Emil ŠVAJDLENKA (203 Česká republika, domácí), A. C. GOREN a Milan ŽEMLIČKA (203 Česká republika, domácí)
Vydání
TURKISH JOURNAL OF PHARMACEUTICAL SCIENCES, CANKAYA-ANKARA, TURKISH PHARMACISTS ASSOC, 2020, 1304-530X
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30104 Pharmacology and pharmacy
Stát vydavatele
Turecko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Kód RIV
RIV/00216224:14160/20:00118239
Organizační jednotka
Farmaceutická fakulta
UT WoS
000585327200011
Klíčová slova anglicky
Anticholinesterase; HPLC; isolation; Lysimachia; tyrosinase
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 24. 2. 2021 08:03, Mgr. Hana Hurtová
Anotace
V originále
Objectives: The scope of the present study was to specify the therapeutic potential for neurodegenerative diseases through evaluating cholinesterase and tyrosinase (TYR) inhibitory and antioxidant activity of Lysimachia verticillaris (LV), and to isolate the major compounds considering the most active fraction. Materials and Methods: The methanol extract (ME) of LV and the chloroform, ethyl acetate (EtOAC), and aqueous fractions obtained from it were used for biological activity and isolation studies. The ME and all fractions were tested for their acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and TYR inhibitory and antioxidant potentials using ELISA microtiter assays. Seven major compounds were isolated from the active EtOAC fraction by semi-preparative high performance liquid chromatography. The structures of the compounds were elucidated by several spectroscopic methods. Results: Marked AChE inhibitory activity was observed in the EtOAC fraction (6337 +/- 1.74%), BChE inhibitory activity in the ME and EtOAC fraction (85.84 +/- 3.01% and 83.82 +/- 3.93%), total phenol content in the EtOAC fraction (261.59 +/- 3.95 mg equivalent of gallic acid/1 g of extract) and total flavonoid contents in the EtOAC fraction (515.54 +/- 2.80 mg equivalent of quercetin/1 g of extract), and 2,2-diphenyl-1-picrylhydrazyl radical scavenging activity and ferric-reducing antioxidant power values in the aqueous and EtOAC fractions (92.54 +/- 0.67%, 92.11 +/- 0.30%; 2.318 +/- 0.054, 2.224 +/- 0.091, respectively). Accordingly, the isolation studies were carried out on the EtOAC fractions. Compounds 1-7 (gallic acid, (+)-catechin, myricetin 3-O-arabinofuranoside, myricetin 3-O-alpha-rhamnopyranoside, quercetin 3-O-beta-glucopyranoside, quercetin 3-O-arabinofuranoside, and quercetin 3-O-alpha-rhamnopyranoside, respectively) were isolated from the active EtOAC fraction. Conclusion: LV may be a potential herbal source for treatment of neurodegenerative diseases based on its strong antioxidant activity and significant cholinesterase inhibition similar to that of the reference.